Paper Details
- Home
- Paper Details
Soluble VEGF receptor-2 may be a predictive marker of anti-angiogenic therapy with clinically available safe agents.
Author: AiharaYosuke, FujimotoMasao, FukuiHiroshi, IkenakaYasuhide, KajiKosuke, KawarataniHideto, MitoroAkira, MoriokaChie, NoguchiRyuichi, SawaiMasayoshi, ShiraiYusaku, ToyoharaMasahisa, TsujimotoTatsuhiro, UemuraMasahito, YamaoJunichi, YoshidaMotoyuki, YoshijiHitoshi
Original Abstract of the Article :
The identification of biomarkers of anti-angiogenic therapy that predict clinical benefit is of vital importance. We previously reported that a combination treatment with clinically available safe agents, specifically angiotensin-converting enzyme inhibitor (ACE-I) and vitamin K (VK), inhibited the ...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412527/
データ提供：米国国立医学図書館（NLM）
Soluble VEGF Receptor-2: A Potential Beacon in the Desert of Anti-Angiogenic Therapy
Cancer, a disease that can feel as vast and unforgiving as a desert, requires innovative treatment approaches. Anti-angiogenic therapy, a treatment strategy that aims to block the growth of new blood vessels that supply tumors, has shown promise in fighting cancer. However, identifying biomarkers that predict which patients will respond to this therapy is crucial. This study explores the potential of soluble VEGF receptor-2 (sVEGFR-2) as a predictive marker for anti-angiogenic therapy.
The researchers investigated the potential of sVEGFR-2 as a predictor of anti-angiogenic therapy response in patients with hepatocellular carcinoma (HCC). The study found that a significant suppression of sVEGFR-2 levels was observed in patients who responded well to a combination of anti-angiogenic agents, suggesting that sVEGFR-2 could serve as a valuable biomarker for predicting treatment response.
Finding the Right Path: Predicting Anti-Angiogenic Therapy Response
This research highlights the potential of sVEGFR-2 as a predictive marker for anti-angiogenic therapy in patients with HCC. The findings suggest that measuring sVEGFR-2 levels could help physicians identify patients who are most likely to benefit from this type of therapy, leading to more personalized and effective treatment strategies.
Navigating the Cancer Desert: A Beacon of Hope in Anti-Angiogenic Therapy
This study encourages further investigation into the use of sVEGFR-2 as a predictive biomarker for anti-angiogenic therapy. The findings suggest that this biomarker could play a crucial role in guiding treatment decisions and optimizing outcomes for patients with cancer.
Dr.Camel's Conclusion
This study explores the potential of sVEGFR-2 as a predictive marker for anti-angiogenic therapy in patients with HCC. The findings suggest that sVEGFR-2 could serve as a valuable beacon for identifying patients who are most likely to benefit from this type of therapy, potentially leading to more personalized and effective treatment strategies.
Date :
- Date Completed n.d.
- Date Revised 2021-10-21
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.